Abstracts tagged "PRO"

Abstract Number: 539 • 2016 ACR/ARHP Annual Meeting
Promis Short Forms Are Relevant to People Living with RA: Results of Cognitive Debriefing Interviews
Anna Kristina Gutierrez¹, Susan J. Bartlett^1,2, Alessandra Butanis³, Vivian P. Bykerk⁴, Jeffrey R. Curtis⁵, Amye L. Leong⁶, Anne Lyddiatt⁷ and Clifton Bingham III⁸, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Strategic Relations, Bone & Joint Decade, Santa Barbara, CA, ⁷Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, ⁸Johns Hopkins University, Baltimore, MD
Background/Purpose: PROMIS® measures were developed to assess physical, mental, and social health across chronic diseases and include brief short forms (SFs; 4-8 items) to assess…
Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Louis Bessette¹, Majed Khraishi², Alan J Kivitz³, Arunan Kaliyaperumal⁴, Rama Grantab⁵, Melanie Poulin-Costello⁵, Maya Isaila⁵ and David Collier⁴, ¹Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
Abstract Number: 1417 • 2016 ACR/ARHP Annual Meeting
Back to Feeling Normal Again: Patients with Rheumatoid Arthritis in Remission
Linda Rasch¹, Maarten Boers^2,3, Willem F. Lems^1,2, Samina Turk⁴, Dirkjan van Schaardenburg^2,5, Tessa Sanderson⁶, Sarah Hewlett⁶ and Lilian van Tuyl¹, ¹Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁵Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁶Nursing and Midwifery, University of the West of England, Bristol, United Kingdom, Bristol, United Kingdom
Background/Purpose: The American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) definition of remission in rheumatoid arthritis (RA) [1] lacks information on patient perceived remission [2].…
Abstract Number: 1741 • 2016 ACR/ARHP Annual Meeting
Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life
Laura C. Coates¹, Philip J Mease², Laure Gossec³, Bruce Kirkham⁴, Lawrence Rasouliyan⁵, Shephard Mpofu⁶, Steffen Jugl⁶, Chetan Karyekar⁷ and Kunal Gandhi⁷, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ³Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ⁴Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, previously demonstrated higher minimal disease activity (MDA)1 response rates and sustained improvements in patient reported outcomes2 among…
Abstract Number: 676 • 2015 ACR/ARHP Annual Meeting
What Proportion of Patients with Psa Fail to Achieve MDA Based on Patient Reported Outcomes? an Analysis from a Prospective, Observational Registry
Proton Rahman¹, J Antonio Avina-Zubieta², Regan Arendse³, William G Bensen⁴, Philip Baer⁵, John Kelsall⁶, Michael Starr⁷, Jacqueline Stewart⁸, Dalton Sholter⁹, Michel Zummer¹⁰, Leo Picard¹¹, Emmanouil Rampakakis¹², Eliofotisti Psaradellis¹³, Karina Maslova¹⁴, Allen J Lehman¹⁴, Francois Nantel^15,16, Cathy Tkaczyk¹⁷ and Brendan Osborne¹⁷, ¹Medicine, Memorial University, St John's, NF, Canada, ²Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ³University of Saskatchewan, Saskatoon, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁶Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁷Rheumatology, McGill University, Montreal, QC, Canada, ⁸Penticton Regional Hospital, Penticton, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ¹¹Rhumatologie Moncton, Moncton, NB, Canada, ¹²JSS Medical Research, St-Laurent, QC, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁶19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹⁷Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Recent treat-to-target guidelines in PsA recommend that minimal disease activity (MDA) is achieved as early as possible. Patient reported outcomes (PROs) have been criticized…
Abstract Number: 1478 • 2015 ACR/ARHP Annual Meeting
Comparison of JIA and RA Patients in the National Data Bank for Rheumatic Diseases
Melissa L. Mannion¹, Sofia Pedro^2,3, Timothy Beukelman⁴, Jeffrey R. Curtis⁵ and Kaleb Michaud³, ¹Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ²Clinical and Translational Research Center, Bioepi, Oeiras, Portugal, ³National Data Bank for Rheumatic Diseases, Wichita, KS, ⁴Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We aimed to compare patient reported outcomes between adults with juvenile idiopathic arthritis (JIA) and adults with rheumatoid arthritis (RA) with similar disease duration…
Abstract Number: 1491 • 2015 ACR/ARHP Annual Meeting
Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Nasir Wabe¹, Michael Sorich², Mihir Wechalekar^2,3, Leslie Cleland³, Leah McWilliams³, Anita Lee^4,5, Llew Spargo⁴, Robert Metcalf³, Cindy Hall⁴, Susanna Proudman^4,5 and Michael D. Wiese⁶, ¹School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁵Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁶University of South Australia, Adelaide, Australia
Background/Purpose: While the introduction of the treat-to-target (T2T) strategy is associated with lower disease activity scores in rheumatoid arthritis (RA), the potential for increased toxicity…
Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Alexandra Steinberg¹, Harinder Chera¹, Yun-Jung Choi¹, Robert Martin¹, Charles McWherter¹, Yunbin Zhang², Pol Boudes¹ and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, ¹Cymabay Therapeutics, Newark, CA, ²INC Research, Raleigh, NC
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
Abstract Number: 2263 • 2015 ACR/ARHP Annual Meeting
Construct and Convergent Validity of Four Global Measures of at-Work Productivity Loss in Patients with Rheumatic Diseases
Sarah Leggett¹, Diane Lacaille², Carina Mihai³, Mihai Bojinca⁴, Brendan van As⁵, Suzanne M. Verstappen⁶ and EULAR-PRO worker productivity group, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre,The University of Manchester, Manchester, United Kingdom, ²Arthritis Research Centre, University of British Columbia, Vancouver, BC, Canada, ³Internal Medicine and Rheumatology, Ion Cantacuzino Hospital, Bucharest, Romania, ⁴Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology, Cantacuzino Hospital, Bucharest, Romania, ⁵Arthritis Research Canada, Richmond, BC, Canada, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Several global measures are available to assess at-work productivity loss in rheumatic diseases. Paucity in research exploring the construct validity of such measures contributes…
Abstract Number: 2602 • 2015 ACR/ARHP Annual Meeting
CCP Antibody Negativity Is Associated with Higher Fatigue in Rheumatoid Arthritis
Laura Cappelli¹, Susan J. Bartlett^2,3, Michelle Jones⁴ and Clifton Bingham⁴, ¹Ste 4500, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ³Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: Fatigue in rheumatoid arthritis (RA) is common and highly debilitating. Emerging evidence suggests that seronegative RA patients differ from their seropositive peers in…
Abstract Number: 2624 • 2015 ACR/ARHP Annual Meeting
Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis
Anna Kristina Gutierrez¹, Michelle Jones², Susan J. Bartlett^1,3,4 and Clifton O. Bingham III², ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada
Background/Purpose: The process of patient reported outcome (PRO) validation requires demonstration that the concept being measured and the patient experience of the corresponding symptom or…
Abstract Number: 2655 • 2015 ACR/ARHP Annual Meeting
Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare
VP Bykerk^1,2, Clifton O. Bingham III³, Ernest H. Choy⁴, Daming Lin², Rieke Alten⁵, Robin Christensen⁶, Daniel E. Furst⁷, Francis Guillemin⁸, Sarah Hewlett⁹, Amye L. Leong¹⁰, Lyn March¹¹, Thasia Woodworth¹², Gilles Boire¹³, Carol Hitchon¹⁴, Shahin Jamal¹⁵, Edward C. Keystone¹⁶, Janet E. Pope¹⁷, J Carter Thorne¹⁸, Diane Tin¹⁹, Susan J. Bartlett^20,21,22 and CATCH Investigators and OMERACT Flare Group, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁵Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁶The Parker instutute, RC, Copenhagen, Denmark, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Lorraine, Nancy, France, ⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹⁰Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹²Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ¹³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁷Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²⁰Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: A reference point for clinically important worsening (CIW) of RA disease activity requiring retreatment or escalation is needed for randomized trials of treatment withdrawal.…
Abstract Number: 1482 • 2014 ACR/ARHP Annual Meeting
Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA)
Rieke Alten¹, Amy Y. Grahn², Patricia Rice³, Robert Holt⁴ and Frank Buttgereit⁵, ¹Charité University Medicine, Berlin, Germany, ²Horizon Pharma, Inc., Deerfield, IL, ³Premier Research, Naperville, IL, ⁴College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ⁵Charité University Hospital, Berlin, Germany
Background/Purpose: RA patients experience stiffness which impacts their daily lives. Although this patient reported symptom was dropped from the RA classification criteria there is growing…
Abstract Number: 942 • 2014 ACR/ARHP Annual Meeting
ACR/EULAR Remission in RA patients in Clinical Practice – Does Substitution of Patient Global with Pain Score Change Remission Rates? Data from the Danish Danbio Registry
Merete Lund Hetland, On behalf of all Depts of Rheumatology in Denmark, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: Modern treatment strategy in RA aims at remission. In 2011, new ACR/EULAR remission criteria were published for patients with RA. Of four Boolean criteria,…
Abstract Number: 356 • 2014 ACR/ARHP Annual Meeting
The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Lena Bugge Nordberg¹, Elisabeth Lie², Anna-Birgitte Aga¹, Marthe Thoresen Maehlen³, Inge Olsen C⁴, Till Uhlig⁴, Tore K. Kvien⁴, Espen A. Haavardsholm⁵ and the Arctic study Group⁵, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The Rheumatoid arthritis impact of disease (RAID) score is a relatively new patient-derived composite score assessing the seven most important domains of the impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].